摘要：

目的分析2012–2014年江苏省6~35月龄儿童肠道病毒71型（EV-A71）中和抗体变化规律及在不同人群中的分布特征。方法 2012年3月至2014年3月，以江苏省赣榆县、射阳县、东海县、宝应县、邳州市和泰兴市为研究现场，依托现场建立的肠道病毒监测系统，结合监护人主动报告和被动就医的方式，对该期间入组的1 276名6~35月龄安慰剂组研究对象进行基线时、随访第1年和第2年定期血清学随访，对发现疑似肠道病毒感染所致疾病患者，采集标本进行EV-A71病原学确诊。采用χ²检验、χ²趋势检验或方差分析分别比较不同特征调查对象EV-A71中和抗体阳性率和抗体几何平均滴度（GMT）水平的差异。结果 2年随访中，EV-A71中和抗体阳性率随着年龄增加而升高（χ²_趋势值分别为39.33、56.41和32.25，P值均<0.001），基线时、随访第1年和第2年分别为22.57%（288/1 276）、37.72%（444/1 177）和42.84%（422/985）；基线时、随访第1年和第2年GMT水平分别为9.95、15.37和24.05（F值分别为22.90、46.36和41.58，P值均<0.001）。2年间，EV-A71年新发感染率分别为13.47%（158/1 173）和20.73%（192/926），其中，319例基线时月龄为24~35的儿童2年间新发感染率较高，基线时至随访第1年为17.87%（57例），随访第1年至第2年为27.20%（65例）；EV-A71中和抗体年衰减率分别为2.81%（33/1 173）和8.10%（75/926）。结论 2012–2014年，江苏省儿童EV-A71中和抗体阳性率和GMT水平随着年龄增长而上升；3~4岁儿童EV-A71新发感染率较高；自然感染后所诱导的EV-A71中和抗体水平可至少维持2年。

关键词：肠道病毒属;中和，抗体;血清流行病学;队列研究

Abstract:

Objective To analyze the dynamic pattern and the distributive characteristics of neutralizing antibody against enterovirus 71 (EV-A71 ) in children aged 6-35 months in Jiangsu province from 2012 to 2014.Methods From March, 2012 to March, 2014, a total of 1 276 children aged between 6 and 35 months were regularly followed up on day 0, year 1 and year 2 for EV-A71 neutralizing antibody test based on the enterovirus surveillance system, with the method of reporting by their guardian or being visited in Ganyu Sheyang Taixing Donghai Pizhou and Baoying in Jiangsu province. At the same time, samples were taken from the suspected persons infected by enterovirus. The χ² test or variance analysis was used to compare the difference of the positive rates and the geometric mean titer(GMT) of EV-A71 neutralizing antibody in different subjects.Results In 2 years follow-up, the positive rates of EV-A71 antibody increased as the growth of the age,and the positive rates on day 0, year 1 and year 2 were 22.57% (288/1 276), 37.72%(444/1 177) and 42.84%(422/985), respectively (χ² values were 39.33, 56.41, 32.25; P< 0.001).The GMTs were 9.95, 15.37 and 24.05, respectively (F values were 22.90,46.36,41.58;P<0.001). In 2 years, the annually new infection rates were 13.47%(158/1 173) and 20.73%(192/926),respectively, and the annually decay rates of EV-A71 antibody were 2.81%(33/1 173) and 8.10%(75/926).Conclusions In 2012 to 2014, the positive rates and the GMTs of EV-A71 antibody of children increased as the growth of the age in Jiangsu. The higher annually new infection rate was in children aged 3 to 4 years. The EV-A71 neutralizing antibody level could maintain at least two years after natural infection.

Key words: Enterovirus;Antibodies, neutralizing;Seroepidemiology;Cohort study

发表日期：2015/12

引用本文：

http://dx.doi.org/10.3760/cma.j.issn.0253-9624.2015.12.006

链接本文：

http://www.pubhealth.org.cn/new/cn/book_show.asp?id=4992

图/表:

10.3760/cma.j.issn.0253-9624.2015.12.006.T001:表1 江苏省不同月龄、性别和地区儿童基线及随访时肠道病毒71型中和抗体阳性情况比较
10.3760/cma.j.issn.0253-9624.2015.12.006.T002:表2 江苏省不同月龄、性别和地区儿童基线及随访时肠道病毒71型中和抗体GMT水平
10.3760/cma.j.issn.0253-9624.2015.12.006.T003:表3 江苏省不同月龄、性别和地区儿童随访时肠道病毒71型新发感染情况
10.3760/cma.j.issn.0253-9624.2015.12.006.T004:表4 江苏省不同月龄、性别和地区儿童随访时肠道病毒71型中和抗体衰减情况

参考文献:

[1]YuCK, ChenCC, ChenCL, et al.Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice[J].J Biomed Sci,2000, 7(6): 523–528.
[2]ZhuF, XuW, XiaJ, et al.Efficacy,safety,and immunogenicity of an enterovirus 71 vaccine in China[J].N Engl J Med, 2014, 370(9):818–828.
[3]ZhuFC, MengFY, LiJX, et al.Efficacy,safety,and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China:a multicentre,randomised,double-blind, placebo-controlled,phase 3 trial[J].Lancet,2013, 381(9882): 2024–2032.
[4]MaoQY, HeP, YuX, et al.Laboratory evaluation of method for determination of neutralizing antibody against human enterovirus 71[J].Chin J Biologicals,2010, 23:885–888.
[5]罗莉，邢薇佳，廖巧红，等．儿童肠道病毒71型和柯萨奇病毒A16型感染血清流行病学研究进展[J]．中华预防医学杂志，2015, 49(2)：184–188.
[6]刘凤仁，刘渠，李刚，等．深圳市龙岗区健康儿童EV71感染血清流行病学研究[J]．华南预防医学，2013, 39(3):40–42.
[7]王金章，陈炜，翁育伟，等．2010年福建省肠道病毒71型血清流行病学调查[J]．中国人兽共患病学报，2015, 31(3): 227–231.
[8]赵生仓，张世杰，岳建宁，等．西宁市儿童人肠道病毒71型血清学调查[J]．中国公共卫生，2011, 27(3):361–362.
[9]侍建波，张廷禄．东海县2008-2011年手足口病流行病学分析[J]．现代预防医学，2014, 41(5):933–935.
[10]张奎，温之花，陈雷，等．2009–2011年邳州市手足口病流行病学分析[J]．中国校医，2012, 26(10):761–762.
[11]OoiEE, PhoonMC, IshakB, et al.Seroepidemiology of human enterovirus 71,Singapore[J].Emerg Infect Dis,2002, 8(9): 995–997.
[12]万俊峰，朱理业，刘红，等．阜阳市手足口病(EV71感染）疫情流行病学分析[J]．安徽医学，2008, 29(4):344–345.
[13]王春荣，关恒云，杨国樑，等．2010-2013年济南地区肠道病毒71型感染手足口病流行病学分析[J]．疾病监测，2015, 30(3):194–197.
[14]张颖，和鹏，陈纯，等．广州市2011年柯萨奇病毒A组6型的分子流行病学特征[J]．中华流行病学杂志，2014, 35(1): 103–104.
[15]ZhuFC, LiangZL, MengFY, et al.Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants[J].PLoS One,2012, 7(5):e37206.
[16]FooDGW, AlonsoS, ChowVTK, et al.Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide[J]. Microbes Infect,2007, 9(11):1299–1306.
[17]YuCK, ChenCC, ChenCL, et al.Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice[J].J Biomed Sci,2000, 7(6): 523–528.
[18]许文波，檀晓娟．肠道病毒71型疫菌使用策略[J]．中华预防医学杂志，2014, 48(6):443–444.
[19]嵇红，毛群颖，王慎玉，等．肠道病毒71型灭活疫苗临床试验的现状与展望[J]．中华预防医学杂志，2014, 48(9): 827–832.

2012–2014年江苏省儿童肠道病毒71型血清流行病学特征

摘要：